Auteur(s) : Harald Gollnick, Carlos Guillén Barona, Ronald GJ Frank, Thomas Ruzicka, Mosaad Megahed, Veronica Tebbs, Mary Owens, Patti Stampone , Universitätsklinik für Dermatologie und Venerologie, Otto-von-Guericke-Universität Magdeburg,Leipziger Str. 44, 39120 Magdeburg, Germany, Instituto Valenciano de Oncología, Profesor Beltrán Báguena, 19, 46009-Valencia, Spain, Medisch Spectrum Twente, Ariensplein 1, 7511 JX, Enschede, Netherlands, Universitätshautklinik Düsseldorf, Moorenstr.5, 40225 Düsseldorf, Germany, 3M Healthcare Limited, 3M House, Morley Street, Loughborough, LE11 1EP, United Kingdom, 3M Pharmaceuticals, 3M Center Building 275-02W-14, St. Paul, Minnesota, 55144-1000 USA.
Illustrations
Figure 1 Subject disposition at each study phase as
of February 16, 2004.
Figure 2 Average maximum severity of LSRs at each
visit as assessed by the investigator, (A) summarizes
erythema, edema, induration, and vesicles, whereas (B)
summarizes erosion, ulceration, scabbing/crusting, and
flaking/scaling.
Figure 3 A representative subject demonstrating the
overall therapeutic cycle for imiquimod 5% cream when used 5 ×/week
for 6 weeks. Photo (A) shows a superficial basal cell
carcinoma (sBCC) on the right upper back prior to treatment with
imiquimod cream, whereas (B) is the same subject after 6
weeks of treatment showing moderate edema and mild erythema,
induration, erosion, and scabbing/crusting. At the 12-week
posttreatment visit (C), this same subject showed moderate
erythema and clinical clearance of the treated sBCC. Photo
(D) is the same subject at month 3 of follow-up showing mild
erythema, edema, and scabbing/crusting. At month 6 of follow-up
(E), only mild erythema was reported. At month 24
(F), all LSRs had resolved and the subject continues to be
clinically clear of sBCC.
Version imprimable
Version PDF
